Welcome to our dedicated page for Mallinckrodt plc news (Ticker: MNK), a resource for investors and traders seeking the latest updates and insights on Mallinckrodt plc stock.
Mallinckrodt plc (MNK) is a global specialty biopharmaceutical and medical imaging company. Headquartered in Dublin, the company is renowned for developing, manufacturing, marketing, and distributing specialty pharmaceutical products and medical imaging agents. Its diverse portfolio spans therapeutic drugs for autoimmune and rare diseases in specialty areas such as neurology, rheumatology, nephrology, ophthalmology, and pulmonology. The company also focuses on immunotherapy, neonatal respiratory critical care therapies, analgesics, and central nervous system drugs.
The company's Specialty Brands segment features a range of branded medicines, while the Specialty Generics segment includes generic drugs and active pharmaceutical ingredients. The Global Medical Imaging segment provides contrast media and nuclear imaging agents. Mallinckrodt's expertise lies in the acquisition and management of highly regulated raw materials, regulatory know-how, and specialized chemistry, formulation, and manufacturing capabilities.
Recent achievements include findings from health economics outcomes research on Acthar® Gel, which were shared at the Academy of Managed Care Pharmacy Nexus 2023. Acthar Gel, approved by the FDA for treating various autoimmune disorders and inflammatory conditions, demonstrated cost-effectiveness for patients with advanced symptomatic sarcoidosis and nephrotic syndrome. Additionally, the company presented new data on TERLIVAZ® at the Society of Critical Care Medicine 2024 Critical Care Congress, showing its efficacy in improving kidney function in adults with hepatorenal syndrome.
Mallinckrodt is committed to continuous innovation, evidenced by the FDA's approval of the Acthar Gel Single-Dose Pre-filled SelfJect™ Injector, designed to provide patients with better control over their medication administration. Financially, Mallinckrodt reported a net sales increase to $467.8 million in Q1 2024, driven by growth in both its Specialty Brands and Specialty Generics segments.
Mallinckrodt plc (NYSE: MNK), a global specialty pharmaceutical company, will announce its first quarter 2023 earnings results on May 9, 2023. The earnings release will cover the financial period ending March 31, 2023. Investors can participate in a conference call scheduled for 8:30 a.m. ET on the same day. Mallinckrodt's operations include the development and distribution of specialty pharmaceutical products focusing on autoimmune and rare diseases, as well as specialty generics.
For further details, investors can access the call registration and audio webcast links provided in the press release. The company is committed to providing timely information through its website.
Mallinckrodt plc (NYSE American: MNK) announced its presentation of two scientific abstracts at the 2023 National Kidney Foundation Spring Clinical Meeting (NKF SCM) in Austin, TX. The abstracts focus on the clinical and health economic outcomes of TERLIVAZ (terlipressin) for adult patients with hepatorenal syndrome (HRS), a serious condition causing rapid kidney function reduction. One abstract evaluates treatment costs for HRS patients, while the other analyzes serum creatinine reduction linked to clinical outcomes. TERLIVAZ is the first FDA-approved treatment to improve kidney function in HRS patients, affecting 30,000 to 40,000 Americans annually. Mallinckrodt aims to raise awareness about HRS's clinical and economic challenges during the meeting.
FAQ
What is the market cap of Mallinckrodt plc (MNK)?
What is Mallinckrodt's core business?
What recent achievements has Mallinckrodt made?
What are the key segments of Mallinckrodt's business?
What is Acthar® Gel?
What is TERLIVAZ® used for?
What financial performance did Mallinckrodt report for Q1 2024?
What new product did Mallinckrodt recently launch?
How does Mallinckrodt support patients using Acthar® Gel?
What is the significance of Mallinckrodt's specialty generics segment?
Where can investors find more information about Mallinckrodt?
